All In Biotech

Drug Trial Radar · NCT07063342

A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses

Phase 1, 4-Part, Open-label (Parts 1 to 3) and Double-blind (Part 4) Study to Evaluate the Pharmacokinetics of Novel KarX (BMS-986519) and KarT (BMS-986520) Prototypes Versus the KarXT (BMS-986510) and KarX-EC (BMS-986519) Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants, and to Evaluate Alternative Formulations of KarX (BMS-986519) and KarXT (BMS-986510) Following Single and Multiple Ascending Doses in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 236 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

236

Planned (sponsor's estimate)

Start

Jun 27, 2025

Primary completion

Mar 29, 2027

Study completion Mar 29, 2027

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate novel KarX and KarT prototypes versus the KarXT and KarX-EC reference following single doses, to explore the effect of food after multiple doses of selected prototypes, and to evaluate alternative formulations of KarX and KarXT following single and multiple ascending doses in healthy adult participants.

Conditions

  • Healthy Volunteers

Interventions

  • Xanomeline/Trospium Chloride CapsuleDrug

    Specified dose on specified days

  • Xanomeline Enteric CapsuleDrug

    Specified dose on specified days

  • Trospium ChlorideDrug

    Specified dose on specified days

  • Xanomeline MRDrug

    Specified dose on specified days

  • XanomelineDrug

    Specified dose on specified days

  • PlaceboDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed concentration (Cmax)Time frame: Up to Day 23
  2. Time of maximum observed concentration (Tmax)Time frame: Up to Day 23
  3. Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))Time frame: Up to Day 23
  4. Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))Time frame: Up to Day 23
  5. Area under the concentration-time curve in 1 dosing interval (AUC(TAU))Time frame: Up to Day 23
  6. Concentration at the end of a dosing interval (Ctau)Time frame: Up to Day 23
  7. Apparent total body clearance (CLT/F)Time frame: Up to Day 23
  8. Effective elimination half-life during dosing interval (T-HALF(eff))Time frame: Up to Day 23
  9. Number of participants with Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 30 days after final dose of study intervention
  10. Number of participants with Serious Adverse Events (SAEs)Time frame: Up to 30 days after final dose of study intervention
  11. Number of participants with Adverse Events of Special Interest (AESIs)Time frame: Up to 30 days after final dose of study intervention
  12. Number of participants with AEs leading to discontinuationTime frame: Up to 30 days after final dose of study intervention
  13. Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences

    Nottingham, Nottinghamshire, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.